Patent · US Active

SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis

US10265314B2 · kind B2 · utility

0Cited by

11References

8Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Peter Sandner · Wuppertal, DE
Johannes-Peter Stasch · Wuppertal, DE
Michael Hahn · Langenfeld, DE
Markus Follmann

Key dates

Filing date	Jul 21, 2014
Grant date	Apr 23, 2019
Priority date	—
Expiry date	Oct 17, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.